Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:aimsTo |
reverse cardiovascular disease
|
| gptkbp:CEO |
gptkb:Matthew_O’Connor
|
| gptkbp:developedBy |
gptkb:drug_candidate_UDP-003
|
| gptkbp:focusesOn |
removal of oxidized cholesterol
treatments for atherosclerosis |
| gptkbp:formerName |
gptkb:Underdog_Pharmaceuticals
|
| gptkbp:foundedIn |
2017
|
| gptkbp:founder |
gptkb:Matthew_O’Connor
gptkb:Aubrey_de_Grey |
| gptkbp:fundedBy |
gptkb:Kizoo_Technology_Capital
gptkb:Longevitytech.fund Other longevity-focused investors |
| gptkbp:headquartersLocation |
gptkb:San_Francisco_Bay_Area
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cyclarity Therapeutics
|
| gptkbp:operatesIn |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:website |
https://cyclaritytx.com/
|
| gptkbp:bfsParent |
gptkb:Laura_Deming
|
| gptkbp:bfsLayer |
6
|